evidence to guide therapy. Yet important questions reMethods. We undertook an evidence-based review of the main unanswered. Finally, the method by which acute literature on continuous renal replacement therapy (CRRT) organ support is provided can have a profound effect on using MEDLINE searches. We determined a list of key questions and convened a 2-day consensus conference to develop patient mortality (e.g., transfusion thresholds [10] and summary statements via a series of alternating breakout and ventilator management [11] ) supporting the need to plenary sessions. In these sessions, we identified supporting identify practice standards and key research questions.
evidence and generated practice guidelines and/or directions The purpose of this consensus conference was to review for future research.
the available evidence regarding the optimal provision
Results. Of the 46 questions considered, we found consensus for 20. We found inadequate evidence for 21 questions and of CRRT, make evidence-based practice recommendafor the remaining five we found data but no consensus. Full tions, and delineate key questions for future study.
versions of workgroup findings are available on the Internet at www. ADQI.net. Conclusions. Despite limited data, broad areas of consensus
METHODS
exist for use of CRRT and guideline development appears feasible. Equally broad areas of disagreement also exist and
Our consensus process relied on evidence where availadditional basic and applied research in acute renal failure is able and, in the absence of evidence, consensus expert needed.
opinion where possible [12] . This combined approach has led previously to important practice guidelines with wide adoption into clinical practice [13] . In contrast, exAcute renal failure (ARF) is a common complication pert opinion alone can ignore important evidence while of critical illness [1, 2] and mortality remains over 50%.
evidence-based reviews can be conceptually flawed withDespite several advances in treatment, consensus over out expert opinion [14] . We conducted the consensus the optimal way to deliver care does not exist. Today, process in three stages: (1) pre-conference, (2) conferapproximately one fourth of all patients in the United ence, and (3) post-conference. States with ARF are treated with continuous renal rePrior to the conference, we identified seven topics of CRRT practice (Table 1) . We selected these topics based we outlined a preliminary set of key questions. We then invited an international panel, predominantly from the but it is unlikely that higher level studies will ever be cles written in other languages were used when identified conducted) [15, 16] . Although there is no consensus on by workgroup members. During this stage, the scope of the exact indications for renal replacement therapy, the conference was also defined and some topics were there is consensus that patients with severe ARF should excluded (Table 1) .
be treated with acute renal replacement therapy (grade We conducted a 2-day conference in August 2000, D). There is significant variation in the timing of intervention using blood urea nitrogen (BUN), creatinine, or in New York, NY. We developed summary statements urine output with up to twofold differences in the rethrough a series of alternating breakout and plenary sesported values of these variables at the time of initiation sions. In each breakout session, the workgroups refined of renal replacement therapy [1, 6, 17, 18] . Thus, no the key questions, identified the supporting evidence, and recommendations on the timing of initiation of renal generated practice guidelines and/or directions for fureplacement therapy are possible beyond those defined ture research as appropriate. We classified evidence by by the conventional criteria that apply to chronic renal levels according to evidence-based medicine methodolfailure patients (diuretic unresponsive pulmonary edema, ogy (Table 2 ) and provided qualitative commentary as hyperkalemia, uremic complications, etc.) (grade D). necessary. However, we deferred critical appraisal of However, since the consequences of these complications individual studies to a later stage. We considered physioare likely to be more severe for critically ill patients with logic, clinical, and economic outcomes separately. We ARF, renal replacement therapy should usually begin generated future research questions by identifying defiprior to their development (grade E). Renal replacement ciencies in the literature and debating whether more therapy should continue as long as the criteria defining evidence was necessary. Where possible, we also considsevere ARF are present (grade E). No further recomered pertinent study design issues. Workgroup members mendations as to discontinuation of renal replacement presented their findings during the plenary sessions, rotherapy can be made. tating responsibility for presenting to ensure full particiIn keeping with the rationale for its development, pation. The workgroups then revised their drafts as CRRT use has generally been reported in severely ill needed until a final version was agreed upon. patients in the intensive care unit. In particular, CRRT A writing committee assembled the individual reports is most often selected for patients with ARF who have from the workgroups and each report was edited to conhemodynamic instability and for patients in whom conform to a uniform style and for length. The final reports tinuous removal of volume or toxic substances is thought were mailed to each participant for comment and revision.
desirable. The latter might include patients with ARF who also have septic shock, acute respiratory distress syn-RESULTS drome (ARDS), burns, or conditions with or, at risk for, We considered a total of 46 questions and our results cerebral edema. In the absence of definitive evidence comparing CRRT to intermittent hemodialyis, no firm overall are summarized in Table 3 . We report a summary of each individual workgroup below. Full versions of workgroup recommendations for patient selection can be made. However, CRRT use may be advantageous in the manfindings are available on the Internet at www.ADQI.net. a A formal evidence-based medicine (EBM) process was not undertaken as part of the consensus conference. However, in five key areas we determined that sufficient evidence exists to warrant such a process. In the case of dialysis membranes, a statistical meta-analysis was recommended, while in the area of catheter design and insertion site, a comprehensive systematic review will be necessary to integrate the data on safety, patency, and recirculation. With regard to dialysis dose and catheter placement, sufficient data exist to establish formal guidelines, although some further study is still required; while, in the case of continuous (CRRT) vs. intermittent therapy, an EBM process will be useful in designing a definitive trial. agement of intensive care unit patients with ARF (grade ing evidence suggests the importance of using standardized Kt/V or equivalent renal clearance to compare dis-E) and CRRT is recommended over intermittent hemodialysis for patients with ARF who have, or are at risk parate therapies and different frequencies of treatment [31] . For pure hemofiltration the ultrafiltration rate and for, cerebral edema (grade C) [19] [20] [21] . There is insufficient evidence to recommend the use of CRRT for nonsieving coefficient for a marker can be used to measure clearance. For other modalities, dialysate plus ultrafil-ARF indications outside clinical investigation (grade E).
Solute control (treatment dose). The exact identity and trate flow and concentration are required to measure clearance (grade C). Clearance is typically factored for relative importance of all uremic toxics are unknown. Despite many decades of research, no single substance surface area, similar to kidney clearance or for urea distribution volume similar to chronic dialysis (grade E). or group of substances have been directly related to adverse effects. Urea is only a marker substance for Treatment dose affects outcome for stable patients with end-stage renal disease (ESRD) [32] , and recent the clinical condition known as uremia [22] . Thus, it is inappropriate to equate the clinical diagnosis of uremia level I [8] and level III [9] evidence supports a similar relationship for patients with ARF. However, there is with isolated blood levels of urea or creatinine (grade C). Absolute levels of urea and creatinine are difficult no consensus on what the minimum dialysis dose should be for ARF. Based on evidence from ESRD, a minimum to interpret as both high and low levels may indicate poor outcome [23] . The rates of change of urea or creatiKt/V of 1.2 should be delivered three times a week to patients with ARF (grade A). However, higher doses of nine levels may better reflect severity of renal failure (i.e., rapid increases suggesting severe renal dysfunction) dialysis may be beneficial in critically ill patients with ARF based on studies in CRRT (grade B). Specifically, [24] [25] [26] [27] . Accordingly, there is broad consensus that serum levels of urea or creatinine should be interpreted in an intensity of continuous venovenous hemofiltration (CVVH) of 35 mL/kg/hour is associated with improved the context of their rates of change over time (grade C). Similarly, during treatment, clearance of various marker survival compared to 20 mL/kg/hour in critically ill patients with ARF [8] . Finally, following our consensus substances appears to be the best measurement of therapy dose since mass transfer must be interpreted with conference, Schiffl, Lang, and Fischer [33] reported the results of a randomized trial comparing alternate day to steady-state blood levels to reflect clearance. Fractional clearance may be even better. Furthermore, the use of daily intermittent hemodialysis showing a reduction in mortality from 46% to 28%. Unfortunately, although blood solute concentrations to assess clearance must consider solute generation rates [28] [29] [30] . Therefore, marker the prescribed dose of dialysis was 3.6 Kt/V per week in the alternate day group, the delivered dose was far less clearance should be used as the primary basis for CRRT dosing (grade C), excepting that during pure filtration, (about 2.8), leaving the issue of a minimum weekly dose of intermittent hemodialysis still unsettled. However, dose is proportional to ultrafiltration rate. Methods for measuring and expressing CRRT clearance vary widely this latter study does support the concept that a doseresponse relationship exists for dialysis in ARF and sugin clinical practice and include clearance (K) times dialysis duration (t) divided by the volume of distribution gests that the traditional, ESRD-based, dose recommendation may be too low. (V) to yield Kt/V (fractional clearance), or divided by the body surface area (K/SA). Other measures include
Membranes. Based on the clinical evidence at the present time, recommendations about the use or avoidthe solute removal index (SRI), or simply ultrafiltration rate for hemofiltration. There is no consensus as to which ance of specific membranes in CRRT cannot be made. However, until proven otherwise, there is consensus that technique should be used in all clinical situations. Emerg-the use of synthetic in favor of cellulose-based mem-(grade C). Femoral vein thrombosis is a significant problem in neonates and young children and, thus, these branes is appropriate [4-7, 34, 35] (grade B). Although not demonstrated conclusively to be of benefit, transvessels should be avoided if possible (grade D). Based on available evidence, no recommendation can be made membrane pressure monitoring and measurement of urea sieving coefficient, urea equilibration ratio, and filregarding the risk of infection with various sites of catheter placement. Recirculation is likely to be significant tration fraction may all be employed to assess filter function (grade E). Filter choice requires special considerfor blood flow rates in excess of 200 mL/min, but will vary depending on catheter design and location. Internal ation for proper implementation of certain modalities, such as high-volume hemofiltration, slow low-efficiency jugular locations are generally superior (grade C). Polyurethane catheters are preferable for CRRT access dialysis (SLED), and extended daily dialysis (EDD). In general we recommend the use of filters with higher (grade D). Silver coating is currently not effective and antibiotic coating/impregnation has not been studied for water permeability for high-volume hemofiltration and dialyzers with large surface areas for SLED and EDD this indication. Vascular access sites should be managed in accord with previously published recommendations [46] . (grade E). Finally, hypersensitivity reactions may occur with certain types of filters. However, there is insufficient Ultrasound guidance has been reported in level II and III studies to reduce the failure and complication rates evidence to produce specific recommendations regarding this issue.
of central venous catheter insertion [47] [48] [49] [50] . Similarly, infection rates and placement failure rates are less when Operational characteristics. Based on the available data, no recommendations regarding the use of predomicatheters are placed by specialized/experienced vascular access teams [51, 52] . Thus, the use of ultrasound guidance nantly convective therapies (i.e., CVVH) as compared to diffusive therapies [i.e., continuous venovenous hemoand specialized access teams is encouraged (grade C).
Anticoagulation. The choice of anticoagulant for CRRT dialysis CVVHD)] can be made. Efficiency of removal of low-molecular-weight solutes is similar with convecshould be determined by patient characteristics, local expertise, ease of monitoring (bed side vs. specialized tion and diffusion. Efficiency of middle-and high-molecular-weight solute removal is greater with convective laboratory tests), and pharmacy issues (including preparing specialized replacement solutions) (grade E). Systherapies; however, there is no evidence that this enhanced solute removal influences clinical outcomes. The temic anticoagulation with heparin (standard unfractionated, low-molecular-weight, or synthetic heparinoids), clinical relevance of differences in solute adsorption is also unknown. Venovenous therapies are preferred to or direct thrombin inhibitors (hirudin and argatroban) should probably be avoided in patients at high risk of arteriovenous therapies due to the ability to provide higher rates of solute clearance [36] and a reduced risk bleeding (grade E). There is no consensus currently on which anticoagulant should be the first choice for all of complications [36, 37] (level III). Arteriovenous therapies should be reserved for settings in which venovenous CRRT patients. In patients who are auto-anticoagulated, or are at high risk of bleeding, consensus exists that therapy cannot be provided due to the absence of adequate equipment or personnel (grade D). There is no CRRT can be carried out successfully without any anticoagulation [53] , although circuit life may be less than consensus regarding the appropriate qualifications for personnel performing CRRT other than demonstration 24 hours (grade D). Regional citrate anticoagulation may also be an option for such patients. of competency. Specifically, there are no data to support the exclusive performance of these therapies by either When anticoagulation is used, safety monitoring is recommended (grade E) although consensus does not intensivists or nephrologists, or by critical care or nephrology nurses. We believe that these decisions need exist on the frequency or method. During heparin anticoagulation, measurement of activated clotting times (ACT) to be resolved at individual health-care facilities, based on available resources and the local competency and or systemic partial thromboplastin time (PTT) are readily available. In addition, routine measurement of platelets credentialing of physicians and nurses (grade E). The criteria for this competency and credentialing have been should be made to monitor for heparin-induced thrombocytopenia. During citrate anticoagulation, frequent meaaddressed by medical and nursing professional societies.
Vascular access. There is currently no consensus on surements of post-filter and serum-ionized calcium should be done to appropriately titrate the dose of citrate and vascular access, although the majority of recently published reports suggest that most centers are now using calcium replacement solutions (grade E). Monitoring of systemic acid-base balance is also advisable in patients single dual-lumen venous catheters. Venous access sites include the subclavian, internal jugular, and femoral at high risk for citrate accumulation. Without additional safety data, regional anticoagulation using heparin-protveins. The optimal site in any given patient is determined by the risks of thrombosis and infection, ease of placeamine cannot be recommended given the risk of protamine accumulation in patients with ARF. Low-molecument, and adequacy of function [38] [39] [40] [41] [42] [43] [44] [45] . Due to the risk of thrombosis and late stenosis, if possible, subclavian lar-weight heparins and synthetic heparinoids require regular monitoring of anti-factor Xa activity (grade E). veins should be avoided for CRRT access in adults There is insufficient evidence to recommend specific Recommendations for reporting of CRRT in the medical literature monitoring strategies for these agents. Similarly, there is no consensus on whether or how to monitor for filter CRRT is defined as any extracorporeal blood purifiperformance during CRRT.
cation therapy intended to substitute for impaired renal Fluid composition and management. Dialysate or subfunction over an extended period of time and applied stitution fluid used during CRRT should contain physiofor, or aimed at being applied for, 24 hours per day. logic concentrations of electrolytes, except in patients Conversely, intermittent therapies are those usually prewith extreme imbalances (grade E). Supra-physiologic scribed for a period of 12 hours or less and include concentrations of glucose found in some dialysis or subtechniques classified as EDD and SLED. While the curstitution fluids frequently result in excessive glucose inrent definitions for the basic modes of CRRT (arterial take and hyperglycemia [54, 55] and therefore should be or pump driven, filtration or dialysis, or both) should avoided (grade E). Both lactate and bicarbonate are able continue to be used ( as a technique that uses a highly permeable dialyzer trated to pH but for anticoagulation, has been associated with blood and dialysate flowing countercurrent. In this with both metabolic alkalosis and metabolic acidosis [58] technique, blood pumps control ultrafiltrate production (level IV). Thus, either lactate or bicarbonate can be and there is a balance of filtration and back-filtration used as buffer in most CRRT patients (grade C), whereas with ultrafiltrate produced in the proximal portion of bicarbonate is preferred in patients with lactic acidosis the fibers and reinfused by back-filtration in the distal and /or liver failure (grade C) and in high-volume hemoportion of the fibers so that replacement fluid is not filtration (grade E). Fluids administered before the required [62, 63] . hemofilter (pre-dilution) appear to enhance the achievContinuous high-volume hemofiltration. Continuous able ultrafiltration rate (this may be especially important high-volume hemofiltration is a variant of CVVH, which in high-volume CVVH) and may be also useful in parequires higher surface area hemofilters and employs ultients with frequent filter clotting (grade E) or, in combitrafiltration volumes greater than 35 mL/hour/kg [63] [64] [65] . nation with post-dilution, when extracorporeal clearance Plasma therapies. The term "plasma therapies" should is limited by the achievable blood flow (grade E). Howbe used for any extracorporeal therapy that requires the ever, no controlled studies provide adequate compariseparation of plasma from the formed elements of blood. sons among these techniques.
The term "hemoperfusion" should be reserved for treatWhile the use of sterile fluid for replacement is imperament in which blood or plasma is exposed to an adsorptive, the bacteriological requirements for CRRT dialytive substance (charcoal, protein A, synthetic materials, sate are less clear, except in high-flux dialysis where monoclonal antibodies, etc.) to remove toxins, solutes, dialysate should probably be sterile because of backor other materials. filtration (grade E). Although reductions of body temTo achieve status of a "new" CRRT technique, it perature below 35ЊC should probably be avoided (grade should be substantially different from existing modal-E), available data do not allow us to make recommendaities. Otherwise these approaches should be classified tions on whether CRRT fluids should be warmed. Inteas a subgroup of an existing modality. Our suggested grated fluid balancing systems have important, albeit "minimal acceptable parameters" for reporting studies theoretical, advantages. While there is no evidence that involving CRRT are shown in Table 5 and are critical fluid removal, per se, improves outcome in critically ill for evaluation of studies using CRRT and comparisons patients with or without ARF, there is limited evidence between CRRT and intermittent therapy. It is recogthat volume overload is associated with adverse outnized that technical reports describing technique modicomes. There is level II evidence to suggest that mainfications without outcome data may only report operataining negative fluid balance decreases length of stay tional characteristics. in the intensive care unit in patients with acute lung inRecommendations for future research in CRRT jury [59] . Therefore, volume overload should be avoided (grade D), especially in patients with acute lung injury Observational/epidemiological studies (grade C). Since adaptive use of intravenous infusion
• Long-term outcomes (survival, quality of life, renal pumps for CRRT has been shown to risk significant erfunction, and need for chronic renal replacement) of rors in fluid balance, these systems should be discouraged ARF, including assessment of the prognostic factors when devices specifically designed for CRRT are availfor these outcomes • Early natural history studies of ARF; ideal characable [60] (grade D). Uncertainty exists as to when to begin renal replace-• Effects of filter characteristics (high permeability, ment therapy and when to stop. In the absence of evihigh adsroptivity) on middle/large molecule redence, issues of timing, dose, and technique remain not moval only variable, but also extremely controversial. CRRT is sometimes used for non-ARF indications, even though Meta-analysis/systematic review there are no established non-ARF indications. Perhaps • Better characterization of the potential for adverse the most pressing clinical question regarding the use of events related to blood-membrane interactions in CRRT is to determine what patient and/or environmenspecific patient populations and with specific filters; tal characteristics make CRRT desirable. Specifically, conflicting evidence needs to be reconciled does CRRT offer an important survival advantage over • The risks of vascular thrombosis and infection with intermittent hemodialysis in the management of ARF vascular access for CRRT in adults and children [70] ? Although combing evidence from multiple small along with the effects of different catheter designs, reports appears to demonstrate a small survival advaninsertion site, catheter tip location and anticoagulatage with CRRT versus hemodialysis [66] , definitive evition on catheter performance and recirculation dence is lacking. Thus, a large prospective RCT of CRRT rates; existing evidence needs to be integrated versus intermittent hemodialysis in intensive care unit patients with ARF is urgently needed. This study should DISCUSSION feature careful "phenotyping" of patients, stratified ranAfter nearly a quarter of a century of clinical use domization of key subgroups (e.g., severity of illness), and despite growing acceptance, there remain significant standardization of dialytic treatment (including dose and deficiencies in our knowledge regarding CRRT and this membrane), and co-interventions (including drug use, has led to variation in practice. However, despite a paunutrition, and non-renal organ support). Of note, the city of level I evidence, there are broad areas of consenconsistent difference in baseline severity of illness, where sus in the practice of CRRT. There are also limited areas CRRT patients are sicker, raises concern that physicians where adequate data exist but where controversy perinvolved in the study of CRRT may be reluctant to ransists. In some cases (membrane biocompatibility, cathedomize sicker patients to intermittent hemodialysis. Thus, analogous to evaluation of the pulmonary artery ter design and insertion site) standard evidence-based
